B cells, or B lymphocytes, are essential components of the adaptive immune system, responsible for producing antibodies that neutralize pathogens. They arise from stem cells in the bone marrow and develop through a series of stages, resulting in various subtypes with distinct functions. These include short-lived plasmablasts that respond rapidly to infections, and long-lived memory B cells that provide immunity by “remembering” pathogens from past infections. In addition to antibody production, B cells play a key role as antigen-presenting cells (APCs), activating T cells to generate a robust immune response. Advances in understanding B cell biology have highlighted their significance in autoimmune diseases and led to the development of innovative B cell-targeted therapies.
B Cell Development and Maturation
The development of B cells begins with multipotent progenitor cells (MPPs) in the bone marrow. MPPs differentiate into the common lymphoid precursor (CLP), which leads to the B cell lineage. Throughout B cell development, specific signaling molecules and transcription factors (such as PU.1, E2A, and PAX5) are essential for guiding the progression from progenitor stages to fully developed B cells.
A critical step in B cell development is the generation of a functional B cell receptor (BCR). B cells undergo recombination of the immunoglobulin (Ig) gene segments, creating a diverse range of BCRs capable of recognizing unique antigens. Initially, recombination occurs in the heavy chain genes (D-J joining), followed by the assembly of the light chain genes. This process involves proteins like terminal deoxynucleotidyl transferase (TdT) and recombinase-activating genes 1 and 2 (RAG1/2), which promote the diversity of BCRs.
Following successful BCR assembly, B cells proceed through a sequence of developmental stages marked by the expression of IgM on the cell surface. Immature B cells then exit the bone marrow and enter the peripheral bloodstream as transitional B cells, where they undergo further maturation into either circulating or non-circulating B cell subsets.
Subtypes of Mature B Cells and Their Functional Roles
Upon reaching maturity, B cells differentiate into specialized subsets with distinct roles in the immune response:
Follicular (FO) B Cells: Predominantly located in lymph nodes, FO B cells are central to generating high-affinity antibody responses in germinal centers (GCs).
Marginal Zone (MZ) B Cells: Found mainly in the spleen, MZ B cells respond rapidly to blood-borne antigens and are crucial for initiating immune responses to encapsulated bacteria.
Memory B Cells: These cells “remember” previous infections and are capable of mounting a quick and robust response upon re-exposure to the same pathogen.
Plasma Cells: Derived from activated B cells, plasma cells secrete large amounts of antibodies into the bloodstream, conferring immediate immunity against pathogens.
B Cell Activation: T Cell-Dependent and Independent Pathways
B cells can be activated via two main pathways: T cell-dependent and T cell-independent, depending on the type of antigen encountered.
Therapeutic Targeting of B Cells in Disease
Due to their involvement in immune regulation, B cells are implicated in a range of autoimmune diseases and cancers. Aberrant B cell activity contributes to the pathogenesis of conditions like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Therapies that target specific B cell markers or pathways aim to mitigate these pathological immune responses.
Monoclonal antibodies targeting surface markers are among the most successful therapies for B cell-mediated diseases:
CD20: Rituximab, a chimeric anti-CD20 antibody, was the first B cell-targeting therapeutic. It depletes CD20-positive B cells, helping treat B cell lymphomas and autoimmune diseases. Variants of Rituximab, such as Ofatumumab and Ocrelizumab, are designed for more specific disease profiles.
CD19: Targeted by MEDI-551, an affinity-optimized monoclonal antibody, CD19 is expressed on plasmablasts and some plasma cells. MEDI-551 induces antibody-dependent cellular cytotoxicity (ADCC), efficiently depleting pathogenic B cells in lymphoid tissues.
CD22: Epratuzimab, a monoclonal antibody targeting CD22, triggers modest ADCC and can modulate B cell receptor signaling, offering an approach for autoimmune disease management.
Inhibiting B Cell Survival Factors
Targeting the B lymphocyte stimulator (BLyS) has proven effective in treating B cell diseases. BLyS promotes B cell survival, and its neutralization induces apoptosis in B cells. Belimumab, an anti-BLyS antibody, is approved for SLE treatment, while Atacicept, a TACI-Ig fusion protein, binds both BLyS and APRIL to inhibit B cell maturation.
Modulating B Cell-T Cell Interactions and Intracellular Functions
Therapies that disrupt B cell-T cell interactions are also being investigated. Monoclonal antibodies that block CD40L prevent T cell-mediated B cell activation, though early trials showed platelet aggregation risks. Modified formats, such as the CD40L Fab fragment CDP7657, minimize these risks and are under investigation for SLE treatment.
References:
Akkaya, M., Kwak, K., & Pierce, S. K. (2019). B cell memory: building two walls of protection against pathogens. Nature Reviews Immunology, 20(4), 229–238. https://doi.org/10.1038/s41577-019-0244-2
Elena, L., & Lopera, D. E. (2013, July 18). Introduction to T and B lymphocytes. Nih.gov; El Rosario University Press. https://www.ncbi.nlm.nih.gov/books/NBK459471/
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
